Thermo Fisher – Optimising Coeliac Disease Diagnosis

While the majority of epidemiological data pertaining to Coeliac Disease (CeD) has originated from Europe and other parts of the world with predominantly Caucasian populations, current evidence estimates that the global prevalence of CeD is 0.7%.¹

The incidence of CeD has been shown to be higher for women versus men (17.4 per 100,000 person-years vs. 7.8 per 100,000 person-years, respectively), and pooled incidence rates have shown a substantial increase of 7.5% per year starting from the latter half of the 20th century.²

The impact of CeD has evolved to global prominence due to its significant burden,² resulting in a crucial need for increased awareness of CeD testing, especially given the high prevalence of people with CeD who remain undiagnosed.³

Recent advancements in diagnostics, such as the advent of anti-tTG IgA autoantibody tests along with growing support for more systematic diagnostic algorithms based on serology, have changed the approach and criteria clinicians use for diagnosis.^4,5

References:

1. Singh P, et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-36 e2.
2. King JA, et al. Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2020;115(4):507-25.
3. Fuchs V, et al. Delayed celiac disease diagnosis predisposes to reduced quality of life and incremental use of health care services and medicines: A prospective nationwide study. United European Gastroenterol J. 2018;6(4):567-75.
4. Al-Toma A, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019;7(5):583-613.
5. National Institute for Health and Care Excellence. Celiac disease: Recognition, assessment and management. 2019.

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.